You are here: Home » PTI Stories » National » News
Business Standard

Apollo, RMS launch cell therapy for orthopaedic patients

Press Trust of India  |  New Delhi 

Apollo Hospitals has tied up with biotechnology firm Regenerative Medical Services (RMS) to launch cell therapy for bone and cartilage defects.

The companies however did not share the financial details of the partnership.

The two cell therapy products - Ossron and Chondron - will address the unmet clinical needs in the bone and cartilage treatments respectively, the companies said.

As part of the pact, the treatment will be made available across all Apollo Hospitals within next six months.

"Our hospitals provide the best medical outcomes at very affordable rates, that is the reason that people from around 150 countries come to India for treatment", Apollo Hospitals Founder-Chairman Prathap C Reddy told reporters here today.

Apollo's association with Regenerative Medical Services is a step to inspire talent in India to further the advancement in developing innovative healthcare treatments to reduce the growing disease burden in the country, he added.

RMS Founder and CEO Yash Sanghavi said it has taken eight years of effort and innovative research to develop the two products that will change the modalities for bone and cartilage treatment in India.

Apollo Hospitals has 9,215 beds across 64 hospitals. It also has 2,500 pharmacies, over 90 primary care and diagnostic clinics and more than 110 telemedicine centres.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Mon, June 19 2017. 16:28 IST